Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].

Saved in:
Bibliographic Details
Title: Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
Authors: Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Wysocki J; Poznan University of Medical Sciences, Poland., Szenborn L; Wroclaw Medical University, Poland., Carmona-Martinez A; Instituto Hispalense de Pediatría, Sevilla, Spain., Poder A; Clinical Research Center, Tartu, Estonia., Dagan R; The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel., Richmond P; Telethon Kids Institute and School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia., Gilbert C; Merck & Co., Inc., Rahway, NJ, USA., Trudel MC; Merck Canada Inc., Kirkland, QC, Canada., Flores S; Merck & Co., Inc., Rahway, NJ, USA., Lupinacci R; Merck & Co., Inc., Rahway, NJ, USA., McFetridge R; Merck & Co., Inc., Rahway, NJ, USA., Wiedmann RT; Merck & Co., Inc., Rahway, NJ, USA., Chen Q; Merck & Co., Inc., Rahway, NJ, USA., Gerrits H; MSD B.V., OSS, the Netherlands., Banniettis N; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: natalie.banniettis@merck.com., Musey L; Merck & Co., Inc., Rahway, NJ, USA., Bickham K; Merck & Co., Inc., Rahway, NJ, USA., Kaminski J; MSD (UK) Limited, London, United Kingdom.
Corporate Authors: V114-025 PNEU-PED-EU-1 study group
Source: Vaccine [Vaccine] 2025 Feb 27; Vol. 48, pp. 126628. Date of Electronic Publication: 2025 Jan 20.
Publication Type: Published Erratum
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2024.126628